In a move that could reshape the landscape of preclinical drug development, the Food and Drug Administration (FDA) recently announced a plan to phase out its requirement for use of animal models in evaluating monoclonal antibodies (mAbs) and other drug candidates.
The SoHo Telemetry System revolutionizes small animal model research by enabling real-time physiological monitoring alongside behavioral analysis without disrupting natural movement. With wireless efficiency, extended transmission distance, and seamless integration, SoHo enhances studies in stress, neuroscience, sleep, motor disorders, cognition, and metabolism. Researchers gain greater accuracy, efficiency, and reproducibility, making SoHo a game-changer in preclinical research.
Organoid electrophysiology is providing pharmaceutical and biotech companies with human-relevant models for testing drug efficacy, modeling diseases, and reducing reliance on animal studies, ultimately accelerating the development of safer and more effective therapeutics.
The integration of behavioral telemetry and organoid research is transforming neuroscience and biomedical science by linking cellular models with complex biological behaviors.
Organoid technology is poised to revolutionize the development of brain-controlled prosthetics. By bridging the gap between the body’s central nervous system and a synthetic device, research with neural organoids could lead to the development of prosthetics capable of real-time interaction with the human brain through closed-loop feedback systems. Multielectrode array technology (also called “microelectrode array” or “MEA”) from Multi Channel Systems is ideally suited for studying this complex interaction and developing innovations in prosthetic research.
Unlike traditional MEA recordings that can only measure field potentials, the IntraCell uses a laser to precisely optoporate cardiomyocytes underneath each electrode.
